![Ingmar Bruns](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 100 072 $ am 31.05.2026
Ingmar Bruns is currently the Chief Medical Officer at Zentalis Pharmaceuticals, Inc. He previously held the position of Chief Medical Officer at Trillium Therapeutics, Inc. from 2020 to 2021.
He also worked as the Senior Vice President-Clinical Development at Pieris Pharmaceuticals, Inc. Dr. Bruns obtained a doctorate degree from Universität zu Lübeck.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.04.2026 | 25’018 ( 0.04% ) | 100 072 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 13.11.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| TRILLIUM THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 17.11.2021 |
| PIERIS PHARMACEUTICALS | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Trillium Therapeutics, Inc.
 Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
Universität zu Lübeck
 Universität zu Lübeck Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pieris Pharmaceuticals, Inc.
 Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Zentalis Pharmaceuticals, Inc.
 Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
